Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2 is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody responses in 136 healthcare workers (HCW) 16-18 weeks after United Kingdom lockdown, 76 of whom had mild/asymptomatic SARS-CoV-2 infection captured by serial sampling. Neutralizing antibodies (nAb) were present in 89% of previously infected HCW. T cell responses tended to be lower following asymptomatic infection than in those reporting case-definition symptoms of COVID-19, while nAb titers were maintained irrespective of symptoms. T cell and antibody responses were sometimes discordant. Eleven percent lacked nAb and had undetectable T cell responses to spike protein but had T cells reactive with other SARS-CoV-2 antigens. Our findings suggest that the majority of individuals with mild or asymptomatic SARS-CoV-2 infection carry nAb complemented by multispecific T cell responses at 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection.

More information Original publication

DOI

10.1126/sciimmunol.abf3698

Type

Journal article

Publication Date

2020-12-01T00:00:00+00:00

Volume

5

Addresses

D, e, p, a, r, t, m, e, n, t, , o, f, , I, n, f, e, c, t, i, o, u, s, , D, i, s, e, a, s, e, ,, , I, m, p, e, r, i, a, l, , C, o, l, l, e, g, e, , L, o, n, d, o, n, ,, , L, o, n, d, o, n, ,, , U, K, .

Keywords

COVIDsortium investigators, COVIDsortium immune correlates network, T-Lymphocytes, Humans, Antibodies, Viral, Case-Control Studies, Cross-Sectional Studies, Antibodies, Neutralizing, Asymptomatic Infections, COVID-19, SARS-CoV-2